Margaret von Mehren, John M Kane, Mark Agulnik, Marilyn M Bui, Janai Carr-Ascher, Edwin Choy, Mary Connelly, Sarah Dry, Kristen N Ganjoo, Ricardo J Gonzalez, Ashley Holder, Jade Homsi, Vicki Keedy, Ciara M Kelly, Edward Kim, David Liebner, Martin McCarter, Sean V McGarry, Nathan W Mesko, Christian Meyer, Alberto S Pappo, Amanda M Parkes, Ivy A Petersen, Seth M Pollack, Matthew Poppe, Richard F Riedel, Scott Schuetze, Jacob Shabason, Jason K Sicklick, Matthew B Spraker, Melissa Zimel, Lisa E Hang, Hema Sundar, Mary Anne Bergman
Soft tissue sarcomas (STS) are rare malignancies of mesenchymal cell origin that display a heterogenous mix of clinical and pathologic characteristics. STS can develop from fat, muscle, nerves, blood vessels, and other connective tissues. The evaluation and treatment of patients with STS requires a multidisciplinary team with demonstrated expertise in the management of these tumors. The complete NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Soft Tissue Sarcoma provide recommendations for the diagnosis, evaluation, and treatment of extremity/superficial trunk/head and neck STS, as well as retroperitoneal/intra-abdominal STS, desmoid tumors, and rhabdomyosarcoma...
July 2022: Journal of the National Comprehensive Cancer Network: JNCCN